Detalhe da pesquisa
1.
One-Year Brolucizumab Outcomes in Neovascular Age-Related Macular Degeneration from a Large United States Cohort in the IRIS® Registry.
Ophthalmology
; 130(9): 937-946, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37086857
2.
Factors Linked to Injection Interval Extension in Eyes with Wet Age-Related Macular Degeneration Switched to Brolucizumab.
Ophthalmology
; 130(8): 795-803, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36990322
3.
Vitreoretinal Specialist Use of Ancillary Testing: An IRIS® Registry Analysis.
Clin Ophthalmol
; 17: 3077-3085, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37873056